• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table C22UKPDS model outcomes, mean and 95% confidence intervals

Total QALYs95% confidence intervalsCosts of complications* (£)95% confidence intervals (£)
LowerUpperLowerUpper
Human insulin8.057.568.539,1537,20011,105
Pioglitazone8.037.558.518,8846,95710,810
Glargine8.007.538.489,2157,26911,162
Biphasic analogue8.057.578.539,1537,19211,114
Rosiglitazone7.947.478.409,3267,37511,278
Exenatide8.087.608.559,1527,23511,070
*

Treatment costs are not included, they were added on to the cost outcomes of the UKPDS

Treatment costs are not included, they were added on to the cost outcomes of the UKPDS

From: Appendix C, Health economic analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.